irinotecan has been researched along with palbociclib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dicker, DT; El-Deiry, WS; Zhang, J; Zhao, S; Zhou, L | 1 |
| Warfel, NA | 1 |
2 other study(ies) available for irinotecan and palbociclib
| Article | Year |
|---|---|
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Hypoxia; Cell Survival; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Screening Assays, Antitumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3 beta; HT29 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Inhibitory Concentration 50; Irinotecan; MAP Kinase Signaling System; Piperazines; Protein Stability; Proto-Oncogene Proteins c-akt; Pyridines | 2017 |
Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.
Topics: Cell Death; Colorectal Neoplasms; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; Humans; Hypoxia; Irinotecan; Piperazines; Pyridines | 2017 |